Koji Izutsu

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · The Lancet · 2022 · 704 citations

Second-line Treatment, Salvage Chemotherapy, Interim Analysis +9

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

Keisuke Kataoka, Yuichi Shiraishi, Yohei Takeda et al. · Nature · 2016 · 627 citations

Aberrant Pd-l1 Expression, Cancer Cell Biology, Pathology +5

Somatic RHOA mutation in angioimmunoblastic T cell lymphoma

Mamiko Sakata‐Yanagimoto, Terukazu Enami, Kenichi Yoshida et al. · Nature Genetics · 2014 · 625 citations

Lymphoid Neoplasia, Somatic Variant, Immunology +4

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

Motoko Yamaguchi, Yok‐Lam Kwong, Won Seog Kim et al. · Journal of Clinical Oncology · 2011 · 596 citations

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 528 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8